https://www.selleckchem.com/pr....oducts/Gefitinib.htm
Differences in quality-adjusted life-year (QALY) were smaller than 0.1 for both populations. PSA results showed that tofacitinib has a high probability of being cost-effective (bio-naïve 82.5%; bio-experienced 90.6%) versus vedolizumab. From the Spanish NHS perspective, tofacitinib could be a dominant treatment (less costly and more effective) in comparison to vedolizumab, with relevant cost savings and similar QALY gains. From the Spanish NHS perspective, tofacitinib could be a dominant treatment (less costly and more effective) in c
Curtir
Comentario
Compartilhar
